STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Camurus (NASDAQ STO:CAMX) today announces that they have granted R-PHARM US (Princeton, NJ) the exclusive license and distribution rights for episil® oral liquid in the US. episil® oral liquid, is a unique and effective treatment for the pain of oral mucositis, a treatment-limiting side effect of cancer therapies, as well as other oral lesions. Financial terms under this agreement are not disclosed. About oral mucositis Oral mucositis (OM) is a commo
![]()
↧